Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Projects and Technology
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Projects and Technology
    • Veterinary Medicine
      • Paccal Vet – Dog
      • Paccal Vet – Cat
    • Project Portfolio – Human Pharmaceuticals
      • Cantrixil
      • Apealea
    • XR Drug Delivery Platform
      • Advantages
      • Patent Protection
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact
May 23, 2024

Annual General Meeting 2024

The Annual General Meeting of 2024 in Vivesto AB was held on Thursday, 23 May 2024.

Documents

  • Report from Annual General Meeting in Vivesto AB
    English May 23, 2024
  • Notice of Annual General Meeting 2024
    English April 23, 2024
  • Proxy form
    English April 23, 2024
  • Postal voting form
    English April 23, 2024
  • Remuneration report 2023
    English April 23, 2024
  • The Board of Directors’ proposal on guidelines for remuneration to senior executives
    English April 23, 2024
  • The Nomination Committee’s proposals AGM 2024
    English April 23, 2024
  • The Nomination Committee’s reasoned opinon
    English April 23, 2024
  • Information about proposed Board members
    English April 23, 2024

Share this page

Calendar

  • August 12, 2025
    Interim report Q2 2025
  • November 11, 2025
    Interim report Q3 2025
  • February 12, 2026
    Interim report Q4 2025
All events
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents

Now enrolling:

Paccal Vet hemangiosarcoma trial

A clinical study for dogs with splenic hemangiosarcoma

Learn more and take survey to see if you may qualify

 

Take me there
Vivesto logo
  • About Us
  • Projects and Technology
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com